The potential for liquid biopsy in early detection in oncology
Researchers and clinicians work with challenges around evolving treatment strategies to keep up with tumor evolution.
Anticipating and out-maneuvering cancer with actionable diagnostic information to impact clinical decision-making during a patient’s treatment journey is a central theme.
At the seminar, you will see user cases involving clinicians treating patients using real-time oncology enabled by de-centralized testing, including an LDT assay, which is currently being used to simultaneously detect ESR1 and PIK3CA mutations in patients with metastatic breast cancer.
The seminar will cover:
- The potential for liquid biopsy in early detection through resistance and recurrence applications;
- Using ctDNA molecular endpoint assays to manage and treat disease in real-time;
- Allowing for more treatment options for patients, along with expanding the utility of drug therapies at earlier stages of disease.
The last day for sign-up is October 20, 2023.
Seats are limited, sign up to the right. Participation is free of charge.
If you are prevented from participating, please let us know as soon as possible.
